Sortera Bio spins out of MRC LMB with revolutionary tech
Its proposition enables the development of novel medicines against challenging biological targets.
Deep Screening facilitates he precise identification of potential therapeutic candidates with desirable drug-like properties by experimentally collecting sequence and functional data in massive parallelism for hundreds of millions of biologics in a single experiment.
These datasets enable the rapid production of internally consistent training datasets and large-scale experimental validation of its generative AI models.
The breakthrough technology powering Sortera Bio was originally developed and validated at the MRC Laboratory of Molecular Biology (MRC LMB), with support from AstraZeneca through the LMB-AstraZeneca Blue Sky Collaboration.
Sortera Bio was founded by Ben Porebski and Philipp Holliger – both recognised leaders in protein engineering and synthetic biology. Porebski, formerly an Investigator Scientist at MRC LMB, is Sortera Bio’s CEO and CTO. Holliger, a Programme Leader at MRC LMB, brings invaluable expertise and strategic guidance to the venture, and serves on its Board.
Porebski says: “We are thrilled to embark on this pioneering journey with the support of our investors and partners. This early support has enabled us to leverage the advantage of our breakthrough technology, with the ambition to rapidly discover precision biologics that can positively impact patients’ lives.”
Jan Löwe, Director of the MRC Laboratory of Molecular Biology, added: “The LMB is proud to have supported the foundational work by Ben and Philipp that generated the powerful technology at the heart of Sortera Bio.
“It is especially important to consider that the technology was developed as part of the LMB's Blue Sky collaboration with AstraZeneca, highlighting the benefits of close cross-sector collaborations.
“Innovation is a key part of what we do and the founding of Sortera Bio continues a long track record of spinning out exciting, useful and high-value companies.”
As Sortera Bio embarks on its mission to advance biological drug discovery, the company welcomes collaboration and partnerships with researchers, pharmaceutical companies, and industry leaders committed to pushing the boundaries of therapeutic innovation.
For more details about the company, email hello@sortera.bio or get in touch via the website – www.sortera.bio
You can also follow Sortera Bio on LinkedIn (https://uk.linkedin.com/company/sortera-bio)
